The contemporary neuropsychiatric landscape across the United States, United Kingdom, Germany, Japan, China, Canada, France, Netherlands, Switzerland, Australia, Dubai, Finland, and Austria is undergoing a profound structural evolution regarding rapid-acting psychoactive substances. As clinical investigators and public health authorities evaluate innovative therapeutic models for treatment-resistant psychological conditions, researchers increasingly analyze compounds that challenge traditional pharmaceutical […]